Phase 1 N=24 IDH1 Peptide Vaccine for Recurrent Grade II Glioma
Brain Cancer · Brain Neoplasm, Primary · Brain Neoplasms, Recurrent
Primary: Percentage of Participants With an Unacceptable Toxicity — 0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=33 Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Gliomas
Primary: Overall Response Rate — 9 percent
Phase 2 N=21 Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Solid Tumor · Glioma · Angioimmunoblastic T-cell Lymphoma
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 3; 4; 6; 7 Participants
Phase 2 N=15 Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
Advanced Solid Tumor · IDH1 Mutation · Glioma
Primary: Best Overall Response — 1; 6 Participants
Phase 2 N=66 BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
IDH1 Mutation · IDH2 Mutation · Recurrent Glioblastoma
Primary: Participants With Dose Limiting Toxicity (DLT) Rate Less Than or Equal to 33% (Dose Level 1) — 0; 7 Participants
Phase 2 N=6 Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma
Glioblastoma
Primary: Number of Dose Limiting Toxicities — 0 Events meeting DLT Criteria
Phase 2 N=345 Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Hematologic Neoplasms
Primary: Phase 1 Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLT) — 0; 0; 0; 0 Participants
Phase 2 N=93 A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme) · Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas) · Cohort 3a and 3b: Chondrosarcoma
Primary: Number of Participants With a Dose Limiting Toxicity (DLT) — 0; 2; 0; 1 Participants
Phase 2 N=160 Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Glioblastoma Multiforme · Glioma · Gliosarcoma
Primary: Frequency of Regimen-Limiting Toxicities (RLTs) in Phase 1 Subjects — 0; 0; 0 Participants
Phase 3 N=187 Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)
Advanced Cholangiocarcinoma · Metastatic Cholangiocarcinoma
Primary: Progression Free Survival (PFS) as Determined by the Independent Radiology Committee (IRC) — 2.7; 1.4 months — p=<0.0001
Phase 2 N=6 Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Accelerated/Blast-phase Myeloproliferative Neoplasm · Chronic-phase Myelofibrosis · IDH2 Mutation
Primary: Number of MPN Participants With Response — 2 Participants
Phase 2 N=17 Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Leukemia · Leukemia, Myeloid · Monocytic Leukemia
Primary: Clinical Response: Hematological Improvement - Erythroid (HI-E) — 0; 0 participants
Phase 2 N=6 Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation
Diffuse Large B Cell Lymphoma
Primary: Number of Participants With Adverse Events, Injection Site Reactions, and Concomitant Medications — 4; 1; 3 Participants
Phase 2 N=8 Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma
Cholangiocarcinoma
Primary: Objective Response Rate (ORR) — 0; 0 Participants
Phase 2 N=37 Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
Acute Myeloid Leukemia · Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 16; 31; 39; 46 Participants
Phase 2 N=50 H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
Diffuse Intrinsic Pontine Glioma · Glioma · Diffuse Midline Glioma, H3 K27M-Mutant
Primary: Percentage of Participants With Adverse Events (AE) Related to Treatment — 5.26; 0; 0; 21.0 percentage of participants
Phase 1 N=13 INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
N/A N=20 Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma
Adult Glioblastoma
Primary: Number of Participants Who Received Treatment Recommendations Within 35 Days of Surgery — 15 Participants
Phase 2 N=26 A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
Recurrent Glioblastoma or Other Glioma Subtypes
Primary: Progression Free Survival — 1.7 months
Phase 3 N=319 An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
Leukemia, Myeloid · Isocitrate Dehydrogenase
Primary: Overall Survival (OS) — 6.5; 6.2 Months — p=0.2288
Phase 2 N=10 Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
MGMT-unmethylated Glioblastoma (GBM) · GBM
Primary: 1-year Overall Survival (OS) — 80 percentage of participants
Phase 2 N=72 Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Colorectal Neoplasms · Microsatellite Instability
Primary: Overall Response Rate (ORR) — 0 % of participants
Phase 3 N=402 Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Metastatic or Unresectable Cutaneous Melanoma
Primary: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 — 2.83; 1.51 Months — p=< 0.001
Phase 1 N=16 Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants
Phase 2 N=194 Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Primary: Progression Free Survival (PFS) — 6.86; 13.00 weeks — p=0.0022
Phase 1 N=15 [F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors
Cancer · Brain Tumors
Primary: Area Under the Receiver Operating Curve (ROC AUC) Values for PET Imaging Techniques — 0.98; 0.91; 0.89; 0.82 Probability
Phase 2 N=336 Indocyanine Green for Central Nervous System Tumors
Suspected Central Nervous System Tumors
Primary: Sensitivity (SBR) — 5.49 ratio
N/A N=3,382 Asia Pacific and Russia Diagnostic Study for EGFR Testing
EGFR Mutation Status in aNSCLC Patients
Primary: Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status — 59.2; 52.0; 77.4; 70.7 Percentage of participants
N/A N=4,240 Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.
Lung Neoplasms
Primary: Number of Participants With Prevalence of Anaplastic Lymphoma Kinase (ALK) Biomarker — 45; 1346; 21; 38 Participants
N/A N=11 Measuring Fatty Acid Oxidation in Gliomas Using 18F-FPIA PET/MRI
Glioma
Primary: Quantitative Measurement of [18F]-FPIA Uptake in Human Gliomas — 0.9041; 1.3529; 2.0470 SUV60_max